0001209191-20-054677.txt : 20201013 0001209191-20-054677.hdr.sgml : 20201013 20201013171055 ACCESSION NUMBER: 0001209191-20-054677 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201009 FILED AS OF DATE: 20201013 DATE AS OF CHANGE: 20201013 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pasquale Maria E CENTRAL INDEX KEY: 0001736295 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 201237308 MAIL ADDRESS: STREET 1: C/O INCYTE CORPORATION STREET 2: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER NAME: FORMER CONFORMED NAME: Pasquale Maria P DATE OF NAME CHANGE: 20180402 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-09 0 0000879169 INCYTE CORP INCY 0001736295 Pasquale Maria E 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 0 1 0 0 EVP & General Counsel Common Stock 2020-10-09 4 M 0 1423 68.62 A 29754 D Common Stock 2020-10-09 4 S 0 1423 95.00 D 28331 D Common Stock 2020-10-12 4 M 0 128 65.36 A 28459 D Non Qualified Stock Option (right to buy) 68.62 2020-10-09 4 M 0 1423 0.00 D 2028-07-01 Common Stock 1423 10438 D Incentive Stock Option (right to buy) 65.36 2020-10-12 4 M 0 128 0.00 D 2028-04-09 Common Stock 128 3313 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. This includes an aggregate of 22,552 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Beginning April 9, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. /s/ Maria Pasquale 2020-10-13